ClinicalTrials.gg
CompletedNCT07422298Updated Aug 3, 2026

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

A Phase 1 interventional study of BMS-986278 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

  • Female individuals not of and males.
  • Healthy as determined by medical history, physical examination, vital signs, 12-lead , and clinical laboratory assessments.
  • 18 to 55 years of age, inclusive, at the time of signing the with a 18.0 to 32.0 kg/m2, inclusive.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment A

    Drug: BMS-986278

  • Experimental
    Treatment B

    Drug: BMS-986278 · Drug: Placebo

  • Placebo comparator
    Treatment C

    Drug: Placebo

  • Experimental
    Treatment D

    Drug: Placebo · Drug: Moxifloxacin

Interventions

  • Specified dose on specified days

  • DrugPlacebo

    Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)

    Time frame: Up to Day 13

  2. Placebo-corrected change from baseline QTcF (ΔΔQTcF)

    Time frame: Up to Day 13

Secondary outcomes

  1. Change from baseline heart rate (HR)

    Time frame: Up to Day 13

  2. Placebo-corrected change from baseline HR

    Time frame: Up to Day 13

  3. Change from baseline PR interval

    Time frame: Up to Day 13

  4. Placebo-corrected change from baseline PR interval

    Time frame: Up to Day 13

  5. Change from baseline QRS interval

    Time frame: Up to Day 13

  6. Placebo-corrected change from baseline QRS interval

    Time frame: Up to Day 13

  7. Number of participants with categorical outliers for QTcF

    Time frame: Up to Day 13

  8. Number of participants with categorical outliers for HR

    Time frame: Up to Day 13

  9. Number of participants with categorical outliers for PR interval

    Time frame: Up to Day 13

  10. Number of participants with categorical outliers for QRS interval

    Time frame: Up to Day 13

  11. Number of participants with treatment-emergent changes of electrocardiogram (ECG) morphology

    Time frame: Up to Day 13

  12. Change from baseline QTcF (ΔQTcF)

    Time frame: Up to Day 13

  13. Placebo-corrected change from baseline QTcF (ΔΔQTcF)

    Time frame: Up to Day 13

  14. Number of participants with non-serious adverse events (AEs)

    Time frame: Up to approximately 17 weeks

  15. Number of participants with Serious AEs (SAEs)

    Time frame: Up to approximately 17 weeks

  16. Number of participants with AEs leading to study intervention discontinuation

    Time frame: Up to approximately 17 weeks

  17. Number of participants with vital sign abnormalities

    Time frame: Up to approximately 17 weeks

  18. Number of participants with clinical laboratory assessment abnormalities

    Time frame: Up to approximately 17 weeks

  19. Number of participants with 12-lead ECG abnormalities

    Time frame: Up to approximately 17 weeks

  20. Number of participants with physical examination abnormalities

    Time frame: Up to approximately 17 weeks

  21. Maximum observed concentration (Cmax)

    Time frame: Up to Day 13

  22. Time of maximum observed concentration (Tmax)

    Time frame: Up to Day 13

  23. Area under the concentration-time curve in 1 dosing interval (AUC[TAU])

    Time frame: Up to Day 13

07

Study locations

1 site
  • Local Institution - 0001
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Jun 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 20, 2026
StartActual
Feb 19, 2026
Primary completionActual
Jun 14, 2026
CompletionActual
Jun 14, 2026
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422298
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 19, 2026
Primary completion
Jun 14, 2026
Completion
Jun 14, 2026
Last update
Aug 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Admilparant · Moxifloxacin

Start the discussion